{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:48:50Z","timestamp":1765039730649,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Loewe Schwerpunkt","award":["CoroPan (project P4)","CoroPan (project P4)"],"award-info":[{"award-number":["CoroPan (project P4)","CoroPan (project P4)"]}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["FKZ 8033801809","FKZ 8033801809"],"award-info":[{"award-number":["FKZ 8033801809","FKZ 8033801809"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008967","name":"Philipps-Universit\u00e4t Marburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008967","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To date, there is no licensed vaccine for Middle East respiratory syndrome coronavirus (MERS-CoV). Therefore, MERS-CoV is one of the diseases targeted by the Coalition for Epidemic Preparedness Innovations (CEPI) vaccine development programs and has been classified as a priority disease by the World Health Organization (WHO). An important measure of vaccine immunogenicity and antibody functionality is the detection of virus-neutralizing antibodies. We have developed and optimized a microneutralization assay (MNA) using authentic MERS-CoV and standardized automatic counting of virus foci. Compared to our standard virus neutralization assay, the MNA showed improved sensitivity when analyzing 30 human sera with good correlation of results (Spearman\u2019s correlation coefficient <jats:italic>r<\/jats:italic>\u2009=\u20090.8917, <jats:italic>p<\/jats:italic> value\u2009&lt;\u20090.0001). It is important to use standardized materials, such as the WHO international standard (IS) for anti-MERS-CoV immunoglobulin G, to compare the results from clinical trials worldwide. Therefore, in addition to the neutralizing titers (NT<jats:sub>50<\/jats:sub>\u2009=\u20091384, NT<jats:sub>80<\/jats:sub>\u2009=\u2009384), we determined the IC<jats:sub>50<\/jats:sub> and IC<jats:sub>80<\/jats:sub> of WHO IS in our MNA to be 0.67\u00a0IU\/ml and 2.6\u00a0IU\/ml, respectively. Overall, the established MNA is well suited to reliably quantify vaccine-induced neutralizing antibodies with high sensitivity.<\/jats:p>","DOI":"10.1007\/s00430-024-00789-w","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:01:51Z","timestamp":1715241711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative assay to analyze neutralization and inhibition of authentic Middle East respiratory syndrome coronavirus"],"prefix":"10.1007","volume":"213","author":[{"given":"Helena","family":"M\u00fcller-Kr\u00e4uter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanda","family":"Mezzacapo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kl\u00fcver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Baumgart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahita","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-9626","authenticated-orcid":false,"given":"Verena","family":"Kr\u00e4hling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"789_CR1","first-page":"4956","volume":"22","author":"MS Nassar","year":"2018","unstructured":"Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA (2018) Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci 22:4956\u20134961","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"789_CR2","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1038\/s41467-022-31557-0","volume":"13","author":"A Fathi","year":"2022","unstructured":"Fathi A, Dahlke C, Kr\u00e4hling V et al (2022) Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. Nat Commun 13:4182","journal-title":"Nat Commun"},{"key":"789_CR3","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S2666-5247(21)00193-2","volume":"3","author":"M Bosaeed","year":"2022","unstructured":"Bosaeed M, Balkhy HH, Almaziad S et al (2022) Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. Lancet Microbe 3:e11\u2013e20","journal-title":"Lancet Microbe"},{"key":"789_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","volume":"20","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Bittaye M, Flaxman A et al (2020) Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 20:816\u2013826","journal-title":"Lancet Infect Dis"},{"key":"789_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","volume":"20","author":"T Koch","year":"2020","unstructured":"Koch T, Dahlke C, Fathi A et al (2020) Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis 20:827\u2013838","journal-title":"Lancet Infect Dis"},{"key":"789_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41577-020-00471-1","volume":"20","author":"DS Khoury","year":"2020","unstructured":"Khoury DS, Wheatley AK, Ramuta MD et al (2020) Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat Rev Immunol 20:727\u2013738","journal-title":"Nat Rev Immunol"},{"key":"789_CR7","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","volume":"16","author":"KR Bewley","year":"2021","unstructured":"Bewley KR, Coombes NS, Gagnon L et al (2021) Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat Protoc 16:3114\u20133140","journal-title":"Nat Protoc"},{"key":"789_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.108","volume":"58","author":"F Amanat","year":"2020","unstructured":"Amanat F, White KM, Miorin L et al (2020) An in vitro microneutralization assay for SARS-CoV-2 serology and drug screening. Curr Protoc Microbiol 58:e108","journal-title":"Curr Protoc Microbiol"},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/22221751.2019.1659552","volume":"8","author":"C Rohde","year":"2019","unstructured":"Rohde C, Becker S, Kr\u00e4hling V (2019) Marburg virus regulates the IRE1\/XBP1-dependent unfolded protein response to ensure efficient viral replication. Emerg Microbes Infect 8:1300\u20131313","journal-title":"Emerg Microbes Infect"},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.1128\/JVI.00912-14","volume":"88","author":"T Ying","year":"2014","unstructured":"Ying T, Du L, Ju TW et al (2014) Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 88:7796\u20137805","journal-title":"J Virol"},{"key":"789_CR11","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.micinf.2014.11.008","volume":"17","author":"T Ying","year":"2015","unstructured":"Ying T, Li H, Lu L, Dimitrov DS, Jiang S (2015) Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect 17:142\u2013148","journal-title":"Microbes Infect"},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia S, Liu M, Wang C et al (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30:343\u2013355","journal-title":"Cell Res"},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.3201\/eid2510.190497","volume":"25","author":"R Harvey","year":"2019","unstructured":"Harvey R, Mattiuzzo G, Hassall M et al (2019) Comparison of serologic assays for Middle East respiratory syndrome coronavirus. Emerg Infect Dis 25:1878\u20131883","journal-title":"Emerg Infect Dis"},{"key":"789_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41541-023-00692-0","volume":"8","author":"MS Avumegah","year":"2023","unstructured":"Avumegah MS, Mattiuzzo G, S\u00e4rnef\u00e4lt A et al (2023) Availability and use of Standards in vaccine development. NPJ Vaccines 8:95","journal-title":"NPJ Vaccines"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-024-00789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00430-024-00789-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-024-00789-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T08:04:56Z","timestamp":1735200296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00430-024-00789-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1007\/s00430-024-00789-w","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"type":"print","value":"0300-8584"},{"type":"electronic","value":"1432-1831"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study used serum samples collected from an anti-MERS-CoV vaccine trial (phase Ib clinical trial of MVA-MERS-S_DF-1 in healthy individuals, NCT04119440). It was approved by the competent authority and the local ethics committee (protocol number 2020-10180_11-AMG-ff) and was carried out in accordance with the Declaration of Helsinki and the guidelines of the International Conference for Harmonization for Good Clinical Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"6"}}